PMID- 27440734
OWN - NLM
STAT- MEDLINE
DCOM- 20180118
LR  - 20180127
IS  - 2059-2310 (Electronic)
IS  - 2059-2302 (Linking)
VI  - 88
IP  - 3
DP  - 2016 Sep
TI  - Soluble monomers, dimers and HLA-G-expressing extracellular vesicles: the three 
      dimensions of structural complexity to use HLA-G as a clinical biomarker.
PG  - 77-86
LID - 10.1111/tan.12844 [doi]
AB  - The HLA-G molecule belongs to the family of nonclassical human leukocyte antigen 
      (HLA) class I. At variance to classical HLA class I, HLA-G displays (i) a low 
      number of nucleotide variations within the coding region, (ii) a high structural 
      diversity, (iii) a restricted peptide repertoire, (iv) a limited tissue 
      distribution and (v) strong immune-suppressive properties. The physiological 
      HLA-G surface expression is restricted to the maternal-fetal interface and to 
      immune-privileged adult tissues. Soluble forms of HLA-G (sHLA-G) are detectable 
      in various body fluids. Cellular activation and pathological processes are 
      associated with an aberrant or a neo-expression of HLA-G/sHLA-G. Functionally, 
      HLA-G and its secreted forms are considered to be key players in the induction of 
      short- and long-term tolerance. Thus, its unique expression profile and 
      tolerance-inducing functions render HLA-G/sHLA-G an attractive biomarker to 
      monitor the systemic health/disease status and disease activity/progression for 
      clinical approaches in disease management and treatments. Here, we place emphasis 
      on (i) the current status of the tolerance-inducing functions by HLA-G/sHLA-G, 
      (ii) the current complexity to implement this molecule as a meaningful clinical 
      biomarker regarding the three dimensions of structural diversity (monomers, 
      dimers and HLA-G-expressing extracellular vesicles) with its functional 
      implications, and (iii) novel and future approaches to detect and quantify sHLA-G 
      structures and functions.
CI  - (c) 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
FAU - Nardi, F da Silva
AU  - Nardi Fda S
AD  - Institute for Transfusion Medicine, University Hospital Essen, Essen, Germany.
AD  - Laboratory of Immunogenetics and Histocompatibility (LIGH), Federal University of 
      Parana, Genetics Department, Curitiba, Brazil.
AD  - Ministry of Education of Brazil, Capes Foundation, Brasilia, Brazil.
FAU - Konig, L
AU  - Konig L
AD  - Institute for Transfusion Medicine, University Hospital Essen, Essen, Germany.
AD  - Department of Gynecology and Obstetrics, University of Duisburg-Essen, Essen, 
      Germany.
FAU - Wagner, B
AU  - Wagner B
AD  - Institute for Transfusion Medicine, University Hospital Essen, Essen, Germany.
FAU - Giebel, B
AU  - Giebel B
AD  - Institute for Transfusion Medicine, University Hospital Essen, Essen, Germany.
FAU - Santos Manvailer, L F
AU  - Santos Manvailer LF
AD  - Institute for Transfusion Medicine, University Hospital Essen, Essen, Germany.
AD  - Ministry of Education of Brazil, Capes Foundation, Brasilia, Brazil.
FAU - Rebmann, V
AU  - Rebmann V
AD  - Institute for Transfusion Medicine, University Hospital Essen, Essen, Germany.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20160721
PL  - England
TA  - HLA
JT  - HLA
JID - 101675570
RN  - 0 (Biomarkers)
RN  - 0 (HLA-G Antigens)
RN  - 0 (Protein Isoforms)
SB  - IM
MH  - Biomarkers/metabolism
MH  - Extracellular Vesicles/chemistry/*immunology
MH  - Female
MH  - Fetus/immunology
MH  - Gene Expression Regulation
MH  - HLA-G Antigens/chemistry/*genetics/immunology
MH  - Humans
MH  - Immune System Diseases/*diagnosis/genetics/immunology/pathology
MH  - *Immune Tolerance
MH  - Placenta/immunology
MH  - Polymorphism, Genetic
MH  - Pregnancy
MH  - Protein Isoforms/chemistry/genetics/immunology
MH  - Protein Multimerization
MH  - Solubility
OTO - NOTNLM
OT  - HLA-G
OT  - HLA-G monomers
OT  - HLA-G-expressing EVs
OT  - KIR2DL4
OT  - LILRB1
OT  - LILRB2
OT  - extracellular vesicles
OT  - sHLA-G
EDAT- 2016/07/22 06:00
MHDA- 2018/01/19 06:00
CRDT- 2016/07/22 06:00
PHST- 2016/06/29 00:00 [received]
PHST- 2016/06/29 00:00 [accepted]
PHST- 2016/07/22 06:00 [entrez]
PHST- 2016/07/22 06:00 [pubmed]
PHST- 2018/01/19 06:00 [medline]
AID - 10.1111/tan.12844 [doi]
PST - ppublish
SO  - HLA. 2016 Sep;88(3):77-86. doi: 10.1111/tan.12844. Epub 2016 Jul 21.